Yorktown Management & Research Co Inc Takes Position in TransMedics Group, Inc. $TMDX

Yorktown Management & Research Co Inc acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX) during the third quarter, Holdings Channel reports. The firm acquired 3,500 shares of the company’s stock, valued at approximately $393,000.

Several other large investors also recently added to or reduced their stakes in the business. Amalgamated Bank increased its stake in TransMedics Group by 2.5% in the 3rd quarter. Amalgamated Bank now owns 9,827 shares of the company’s stock worth $1,103,000 after acquiring an additional 241 shares during the last quarter. Evergreen Capital Management LLC grew its holdings in shares of TransMedics Group by 18.4% during the third quarter. Evergreen Capital Management LLC now owns 2,676 shares of the company’s stock worth $300,000 after purchasing an additional 415 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new position in shares of TransMedics Group in the third quarter worth approximately $1,597,000. Nordea Investment Management AB purchased a new stake in TransMedics Group in the third quarter valued at approximately $4,070,000. Finally, First Horizon Corp bought a new stake in TransMedics Group during the third quarter valued at approximately $43,000. Institutional investors own 99.67% of the company’s stock.

Insiders Place Their Bets

In related news, Director David Weill sold 5,000 shares of TransMedics Group stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total value of $693,200.00. Following the sale, the director owned 12,134 shares in the company, valued at $1,682,257.76. The trade was a 29.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Gerardo Hernandez sold 920 shares of the business’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total transaction of $128,450.40. Following the transaction, the chief financial officer directly owned 15,064 shares in the company, valued at approximately $2,103,235.68. The trade was a 5.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 13,062 shares of company stock worth $1,797,634. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Trading Down 0.2%

Shares of TMDX opened at $143.37 on Friday. The stock has a market capitalization of $4.90 billion, a P/E ratio of 58.04 and a beta of 2.03. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $156.00. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43. The firm has a fifty day simple moving average of $130.87 and a two-hundred day simple moving average of $122.58.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.37 by $0.29. The firm had revenue of $143.82 million during the quarter, compared to the consensus estimate of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The company’s quarterly revenue was up 32.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.12 earnings per share. On average, research analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on TMDX shares. Zacks Research lowered shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Wall Street Zen upgraded TransMedics Group from a “hold” rating to a “buy” rating in a report on Sunday, December 28th. Morgan Stanley boosted their target price on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Canaccord Genuity Group increased their price target on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of TransMedics Group in a report on Monday, December 22nd. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $144.25.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.